35986841_10216840653711318_1105697261150535680_n
Normal view MARC view ISBD view

An introduction to clinical pharmaceutics / by Alexander T. Florence.

By: Florence, A. T. (Alexander Taylor).
Material type: TextTextPublisher: London : Pharmaceutical Press, 2010Edition: 1st ed.Description: xiii, 179 p. : ill. ; 24 cm.Content type: text Media type: unmediated Carrier type: volumeISBN: 9780853696919 (pbk.); 0853696918 (pbk.).Subject(s): Drugs -- Dosage forms | Pharmaceutical chemistry | Drugs -- Dosage forms -- Case studiesDDC classification: 615.1922
Contents:
1 What is clinical pharmaceutics? ; Introduction ; Physical concepts ; The nature of the dosage form and outcomes ; Quality of effect ; Ingredients in dosage forms and their influence on outcomes ; Conclusion ; References -- 2 Excipients: Not always inert. Introduction ; Usually but not always inert ; E-numbers ; Cross-reactivity ; Dyes used in lymph node identification ; Non-ionic surfactants ; Polyoxyethylene glycols (PEGs) ; Adjuvants as therapeutic substances ; Talc as therapeutic agent and excipient ; Active excipients in multiple therapies ; Conclusions ; References -- 3 Thinking chemically. Introduction ; The chemistry of drugs and clinical pharmaceutics ; Chemical nomenclature ; Surface-active drugs ; Acids and bases ; Structural similarities between drugs ; Cross-reactivity ; Beta-lactam antibiotics and the formation of oligomers ; The bisphosphonates ; Hydrophobic and hydrophilic statins ; Photochemical reactions and photoinduced reactions ; Chelation and tetracyclines ; Sugammedex: a cyclodextrin derivative ; Conclusions ; References -- 4 Looking at formulations. Introduction ; Protein drugs and formulations ; Monoclonal antibodies (MAbs) ; Amphotericin B formulations ; A doxorubicin formulation: Doxil ; A propofol formulation: Diprivan ; Long-acting depot injections ; Raft-producing oral formulations ; Etoposide (Vepesid, VP 16 and etoposide phosphate) ; Paclitaxel ; Eutectic mixtures of local anaesthetics ; Ciclosporin (cyclosporin) ; Lupron Depot; Prostap SR and Prostap 3 ; Zoladex ; Fluoroquinolone eye drops ; Ionsys: lontophoretic transdermal device for fentanyl ; Parenterals ; Chloramphenicol ; Materials used in drug delivery ; Conclusions ; References -- 5 Adverse events and formulations and devices. Introduction ; Dosage form type ; Reactions to impurities ; Abnormal bioavailability, high or low ; Testing for adverse effects ; Nanosystems ; Conclusions ; References -- 6 Paediatric, geriatric and special formulations. Introduction ; Extemporaneous formulations ; Effect of formulation and presentation: a case from the literature ; Extemporaneous formulations and performance ; The elderly and their medication ; Enteral feeding ; Drug interactions with nutrient formulations ; Conclusions ; References -- 7 Generic medicines: Conventional drugs and biologicals. Introduction ; Regulatory statements on generic products ; Generics: A question of quality ; Specific conditions and generics ; Reading and deconstructing the literature on bioequivalence ; Antiretroviral drugs ; Bioequivalence of ophthalmic products ; The case of sevoflurane ; Generic biologicals (biologics) ; Conclusions ; References -- 8 The future: Delivery systems for modem therapeutics ; Introduction ; Personalised medicine and medicines ; Drug delivery and personalised medicines ; Technologies ; Nanotechnoiogy ; Cell-based therapies ; Gene therapy ; Conclusions ; References.
Tags from this library: No tags from this library for this title. Log in to add tags.
    Average rating: 0.0 (0 votes)
Item type Current location Call number Status Date due Barcode
Books Books Centeral Library
Second Floor - Pharmacy
615.1922 F.A.I 2010 (Browse shelf) Available 17874

1 What is clinical pharmaceutics? ; Introduction ; Physical concepts ; The nature of the dosage form and outcomes ; Quality of effect ; Ingredients in dosage forms and their influence on outcomes ; Conclusion ; References --
2 Excipients: Not always inert. Introduction ; Usually but not always inert ; E-numbers ; Cross-reactivity ; Dyes used in lymph node identification ; Non-ionic surfactants ; Polyoxyethylene glycols (PEGs) ; Adjuvants as therapeutic substances ; Talc as therapeutic agent and excipient ; Active excipients in multiple therapies ; Conclusions ; References --
3 Thinking chemically. Introduction ; The chemistry of drugs and clinical pharmaceutics ; Chemical nomenclature ; Surface-active drugs ; Acids and bases ; Structural similarities between drugs ; Cross-reactivity ; Beta-lactam antibiotics and the formation of oligomers ; The bisphosphonates ; Hydrophobic and hydrophilic statins ; Photochemical reactions and photoinduced reactions ; Chelation and tetracyclines ; Sugammedex: a cyclodextrin derivative ; Conclusions ; References --
4 Looking at formulations. Introduction ; Protein drugs and formulations ; Monoclonal antibodies (MAbs) ; Amphotericin B formulations ; A doxorubicin formulation: Doxil ; A propofol formulation: Diprivan ; Long-acting depot injections ; Raft-producing oral formulations ; Etoposide (Vepesid, VP 16 and etoposide phosphate) ; Paclitaxel ; Eutectic mixtures of local anaesthetics ; Ciclosporin (cyclosporin) ; Lupron Depot; Prostap SR and Prostap 3 ; Zoladex ; Fluoroquinolone eye drops ; Ionsys: lontophoretic transdermal device for fentanyl ; Parenterals ; Chloramphenicol ; Materials used in drug delivery ; Conclusions ; References --
5 Adverse events and formulations and devices. Introduction ; Dosage form type ; Reactions to impurities ; Abnormal bioavailability, high or low ; Testing for adverse effects ; Nanosystems ; Conclusions ; References --
6 Paediatric, geriatric and special formulations. Introduction ; Extemporaneous formulations ; Effect of formulation and presentation: a case from the literature ; Extemporaneous formulations and performance ; The elderly and their medication ; Enteral feeding ; Drug interactions with nutrient formulations ; Conclusions ; References --
7 Generic medicines: Conventional drugs and biologicals. Introduction ; Regulatory statements on generic products ; Generics: A question of quality ; Specific conditions and generics ; Reading and deconstructing the literature on bioequivalence ; Antiretroviral drugs ; Bioequivalence of ophthalmic products ; The case of sevoflurane ; Generic biologicals (biologics) ; Conclusions ; References --
8 The future: Delivery systems for modem therapeutics ; Introduction ; Personalised medicine and medicines ; Drug delivery and personalised medicines ; Technologies ; Nanotechnoiogy ; Cell-based therapies ; Gene therapy ; Conclusions ; References.

There are no comments for this item.

Log in to your account to post a comment.